The golden hour of prehospital reperfusion with triple antiplatelet therapy: A sub-analysis from the Ongoing Tirofiban in Myocardial Evaluation 2 (On-TIME 2) trial early initiation of triple antiplatelet therapy - 05/08/11
, Jurriën M. ten Berg, MD, PhD c, Jochem W. van Werkum, MD, PhD c, Eric Boersma, MSc, PhD d, Arend Mosterd, MD, PhD e, f, g, Pieter R. Stella, MD, PhD h, Arthur B. van Zoelen, MD c, A.T. Marcel Gosselink, MD, PhD b, Waclav Kochman, MD, PhD i, Thorsten Dill, MD, PhD j, Petra C. Koopmans, PhD k, Gert van Houwelingen, MD l, Felix Zijlstra, MD, PhD m, Christian Hamm, MD, PhD jRésumé |
Background |
It is known that the efficacy of thrombolytic therapy in ST-segment elevation myocardial infarction (STEMI) is highly time dependent with the best efficacy when given within the so-called golden hour. This analysis from the On-TIME 2 trial evaluated the efficacy of triple antiplatelet therapy on initial patency and ST-segment resolution (STR) in relation to time from symptom onset to first medical contact.
Methods |
The On-TIME 2 trial included 1,398 consecutive STEMI patients referred for primary percutaneous coronary intervention (PCI). Patients were randomized to dual (500 mg aspirin and 600 mg clopidogrel) or triple antiplatelet (500 mg aspirin, 600 mg clopidogrel, and tirofiban 25 μg/kg bolus and 0.15 μg/kg per minute maintenance infusion for 18 hours) pretreatment in the ambulance.
Primary outcome of this sub-analysis was initial patency of the infarct-related vessel and STR before PCI according to time from symptom onset to first medical contact in quartiles. In addition, the incidence of aborted myocardial infarction, defined as the absence of a rise in creatinine kinase, was assessed.
Results |
Initial patency, STR before PCI, and the incidence of aborted myocardial infarction gradually increased with shorter time from symptom onset to first medical contact. Initial Thrombolysis in Myocardial Infarction flow was present in 21.2% in the total population and 26.2%, 21.5%, 18.1%, and 18.8% in the time quartiles, respectively (P for trend = .01). The incidence of complete STR pre-angiography was 16.6% in the total population and 23.4%, 18.2%, 14.7%, and 9.9% in the 4 quartiles, respectively (P for trend < .001). This was largely driven by the effect of triple antiplatelet therapy, which further improved initial patency and STR and led to a significantly higher incidence of aborted myocardial infarction (13.2% vs 8.7%, P = .011), especially in the patients with short duration of symptoms.
Conclusion |
Antiplatelet pretreatment before primary PCI, including a glycoprotein IIb/IIIa blocker, seems to be most effective when given shortly after symptom onset. Further studies should be performed to test this hypothesis.
Le texte complet de cet article est disponible en PDF.Plan
| RCT registration no. N06195297. |
Vol 160 - N° 6
P. 1079-1084 - décembre 2010 Retour au numéro
Article précédent
- Changes in glycoprotein IIb/IIIa inhibitor excess dosing with site-specific safety feedback in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) initiative
- Daniel W. Mudrick, Anita Y. Chen, Matthew T. Roe, L. Kristin Newby, W. Brian Gibler, E. Magnus Ohman, Eric D. Peterson, Karen P. Alexander
- ST-Segment resolution and clinical outcome with ischemic postconditioning and comparison to magnetic resonance
- Jacob Lønborg, Lene Holmvang, Henning Kelbæk, Niels Vejlstrup, Erik Jørgensen, Steffen Helqvist, Kari Saunamäki, Peter Clemmensen, Marek Treiman, Jan S. Jensen, Thomas Engstrøm
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?